Abbott Receives FDA's Emergency Use Authorization for its Fourth Ab Blood Test to Detect COVID-19
Shots:
- Abbott’s SARS-CoV-2 IgG lab-based serology blood test is the fourth COVID-19 detection test to receive the FDA’ EUA based on Alinity i platforms- which is a next-generation immunoassay instrument offering efficiency to lab clinicians for running tests
- SARS-CoV-2 IgG lab-based serology blood test is a reliable test for customers and patients to detect Abs with >99.6% specificity and 100% sensitivity in patients tested 14 days post COVID-19 symptoms. Abbott’s SARS-CoV-2 IgG Ab blood test on the ARCHITECT system received the US FDA’s EUA and CE Mark and is also shipped in the US- UK- Italy including Spain and India
- Abbott will ship 30M Ab tests globally by May 2020 with capacity of 60M in Jun 2020 across its ARCHITECT and Alinity i platforms with expected submission for the CE mark to the IVD Directive (98/79/EC) in EU by this week for Alinity i SARS-CoV-2 IgG test
Click here to read full press release/ article | Ref: Abbott | Image:Abbott
Related News : Abbott Launches its Third Test to Detect COVID-19
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
